212-681-1575

In April, MesotheliomaHelp reported on the findings of a phase I clinical trial showing that the five-year survival rate for some lung cancer patients treated with Opdivo (nivolumab), an immunotherapy treatment, was “much higher” than historical data. Now, researchers report ...
Continue Reading

Want Specific topic updates?

Given the staggering number of Americans who die each year from lung cancer, researchers from the University of Kentucky College of Pharmacy, Memorial Sloan Kettering Cancer Center ...

Read Full Story

Want Specific topic updates?

The U.S. Food and Drug Administration announced last month that it has granted Breakthrough Therapy Designation for the drug Imfinzi (durvalumab) in the treatment of non-small cell ...

Read Full Story

Want Specific topic updates?

While MesotheliomaHelp has reported numerous times about research that looks to nature, mostly in fruits and vegetables, to bring new treatments to mesothelioma patients, researche ...

Read Full Story

Want Specific topic updates?

Lung cancer patients with a specific genetic mutation just received good news with the approval of a combination drug treatment. The U.S. Food and Drug Administration announced in ...

Read Full Story

Want Specific topic updates?

1 2 3 43